Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8881509 | 0.84 | APEX1 (0.34) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23729956 | 0.81 | SLC6A3 (0.36) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7176893 | 0.80 | TLR7 (0.37) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL179319 | 0.78 | CCR4 (0.39) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL26742797 | 0.77 | SMN1; SMN2 (0.33) | SLC6A3LMNASMN1; SMN2 | |
| SCHEMBL8802941 | 0.76 | LMNA (0.32) | LMNA | |
| SCHEMBL25998129 | 0.74 | SLC6A3 (0.34) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL22824973 | 0.74 | SLC6A3 (0.35) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL14671448 | 0.73 | CCR4 (0.34) | TLR7 | |
| SCHEMBL9257804 | 0.73 | PIK3CD (0.35) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4034106-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746089-A | Thiazolecarboxamide compounds and their use for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GOT2, ABAT, SDHA | SLC6A3 3507/4885TLR7 242/4885PIK3CD 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.